Last updated on April 2018

The SYMPTOMS - SYstematic Elderly Medical Patients Thromboprophylaxis: Efficacy on Symptomatic OutcoMeS - Study


Brief description of study

Venous thromboembolism (VTE) is a frequent condition, affecting 1.8 per 1,000 people every year. Admission to hospital is one of the main risk factors for VTE, and could account for up to 20% of all VTE, making VTE prevention in admitted patients an appealing option to reduce VTE global burden.

The landmark MEDENOX trial and others demonstrated the efficacy of low molecular weight heparins (LMWH) in reducing a composite outcome of symptomatic and asymptomatic events, the latter accounting for the vast majority of events.

Publication of these trials led to the implementation of thromboprophylaxis policies in hospitals, which acceptance has been variable. More recently, the use of thromboprophylaxis has been challenged after the publication of 1) a negative trial that used 'death from any cause' as main outcome, 2) a systematic review showing the lack of a clear efficacy on the risk of pulmonary embolism or death, 3) negative trials using new oral anticoagulants, 4) the last version of the American College of Chest Physicians Guidelines, focusing on symptomatic events only, downgraded its recommendation for thromboprophylaxis in medical patients to a 1B recommendation, restricting its use to patients 'at increased risk of thrombosis' and recommending against the use of thromboprophylaxis in patients at low risk of thrombosis, patients bleeding or at high risk of bleeding.

However, a limitation of this interpretation of the data is that in most trials, patients with screened asymptomatic events were treated with anticoagulants, preventing the occurrence of symptomatic events during follow-up. Moreover, subgroup analyses showed that elderly patients were at high risk of thrombosis in these trials, and that LMWH could be particularly efficient in this subgroup of patients. Conversely, their risk of bleeding is also higher than in younger patients and the current trials were not powered to detect a difference in the bleeding risk between groups. Finally, the diagnostic and therapeutic management of VTE is more challenging in the elderly. Therefore, we planned a randomized controlled trial on the efficacy of LMWH for the prevention of symptomatic VTE in elderly patients.

Clinical Study Identifier: NCT02379806

Contact Investigators or Research Sites near you

Start Over

Anne BOURGARIT-DURAND, Pr

H pital Jean Verdier (APHP)
Bondy, France
1.04miles
  Connect »

Marilucy LOPEZ-SUBLET, Dr

CHU Avicenne (APHP)
Bobigny, France
3.94miles
  Connect »

Arsène MEKINIAN, Dr

H pital Saint-Antoine (APHP)
Paris, France
6.51miles
  Connect »

Guy MEYER, Pr

HEGP - Paris
Paris, France
6.7miles
  Connect »

Jean-François BERGMANN, Pr

H pital Lariboisiere
Paris, France
6.7miles
  Connect »

Claire LEJEUNNE, Pr

H pita Cochin - APHP
Paris, France
9.72miles
  Connect »

Pierre CHARLES, Dr

Institut Mutualiste Montsouris
Paris, France
9.72miles
  Connect »